Insmed Inc (OQ:INSM)

Business Focus: Bio Therapeutic Drugs

Mar 27, 2024 04:05 pm ET
Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker—
Feb 22, 2024 06:00 am ET
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024—
Feb 08, 2024 07:00 am ET
Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024
BRIDGEWATER, N.J., Feb. 8, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth-quarter and full year 2023 financial results on Thursday, February 22, 2024.
Feb 02, 2024 03:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Feb. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 05, 2024 07:00 am ET
Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
—ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million—
Jan 04, 2024 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Jan. 4, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 02, 2024 07:00 am ET
Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2024, at 3:00 p.m. PT/6:00 p.m. ET.
Dec 05, 2023 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Dec. 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 14 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 29, 2023 07:00 am ET
Insmed To Present at the Nasdaq 49th Investor Conference
BRIDGEWATER, N.J., Nov. 29, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 49th Investor Conference in London on Wednesday, December 6, 2023, at 8:30 a.m. ET/1:30 p.m. GMT.
Nov 08, 2023 07:00 am ET
Insmed To Present at Two November Conferences
BRIDGEWATER, N.J., Nov. 8, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
Nov 03, 2023 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 21 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 02, 2023 08:00 am ET
Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe
— Company-wide day of service brings more than 700 employees together to volunteer in 25 locations throughout the U.S., Europe, and Japan —
Oct 26, 2023 04:05 pm ET
Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List
-- Insmed Leads Science Top Employers List for Third Consecutive Year --
Oct 26, 2023 07:30 am ET
Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022—
Oct 24, 2023 08:00 am ET
Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI
BRIDGEWATER, N.J., Oct. 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, today announced a collaboration with Google Cloud to transform the drug discovery, development, and commercialization landscape of the life sciences industry through the use of generative AI. This alliance will harness the power of Google Cloud's cutting-edge AI technology and Insmed's expertise in serious and rare diseases with a clear goal of reducing the time and increasing the efficiency of developing and delivering new medicines to appropriate patients.
Oct 12, 2023 08:00 am ET
Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023
BRIDGEWATER, N.J., Oct. 12, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third-quarter 2023 financial results on Thursday, October 26, 2023.
Oct 06, 2023 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Oct. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 16 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Sep 26, 2023 08:00 am ET
Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference
BRIDGEWATER, N.J., Sept. 26, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at Chardan's 7th Annual Genetic Medicines Conference in New York, on Tuesday, October 3, 2023 at 2:00 p.m. ET.
Jul 20, 2023 08:00 am ET
Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023
BRIDGEWATER, N.J., July 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second-quarter 2023 financial results on Thursday, August 3, 2023.
Jul 07, 2023 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., July 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jun 07, 2023 08:00 am ET
Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference
BRIDGEWATER, N.J., June 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA, on Wednesday, June 14, 2023 at 1:20 p.m. PT (4:20 p.m. ET).
Jun 06, 2023 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 34 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 22, 2023 04:05 pm ET
Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW Subgroup Analysis—
May 08, 2023 07:30 am ET
Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"
—Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025—
May 05, 2023 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., May 5, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 04, 2023 07:30 am ET
Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
—Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024—
Apr 24, 2023 08:00 am ET
Insmed to Host Investor and Analyst Event on May 8, 2023
— The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More—
Apr 20, 2023 08:00 am ET
Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023
BRIDGEWATER, N.J., April 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2023 financial results on Thursday, May 4, 2023.
Apr 06, 2023 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., April 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Mar 31, 2023 08:00 am ET
Mar 24, 2023 04:22 pm ET
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease (COPD) to Be Shared in Oral Presentation—
Feb 09, 2023 07:00 am ET
Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023
BRIDGEWATER, N.J., Feb. 9, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023.
Feb 07, 2023 07:00 am ET
Insmed To Present at the SVB Securities Global Biopharma Conference
BRIDGEWATER, N.J., Feb. 7, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET.
Feb 03, 2023 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Feb. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 26, 2023 10:45 am ET
Analysts and Executives Converge February 2nd at the 30th Annual Emerald Groundhog Day Investment Forum
Emerald Advisers, LLC celebrated 30 years of managing client funds in 2022, and its portfolio managers and research analysts help kick off 2023 by presenting their insights and outlook for the new year at the 30th Annual Groundhog Day Investment Forum on February 2nd in King of Prussia, PA.
Jan 20, 2023 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Jan. 20, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 06, 2023 07:00 am ET
Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference
—Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses—
Jan 03, 2023 07:00 am ET
Insmed To Present at the 41st Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 3, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2023 at 4:30 p.m. PT (7:30 p.m. ET).
Dec 06, 2022 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Dec. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 30, 2022 07:00 am ET
Insmed To Present at the Nasdaq 47th Investor Conference
BRIDGEWATER, N.J., Nov. 30, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47th Investor Conference in London on Wednesday, December 7 at 8:30 a.m. EST/1:30 p.m. GMT.
Nov 04, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 01, 2022 08:00 am ET
Insmed To Present at Three November Conferences
BRIDGEWATER, N.J., Nov. 1, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
Oct 27, 2022 04:05 pm ET
Insmed Ranks No. 1 on Science's 2022 Top Biopharma Employers List
--Insmed Leads Science Top Employers List for Second Year in a Row--
Oct 27, 2022 07:30 am ET
Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch—
Oct 19, 2022 08:50 am ET
Insmed Announces Strategic Financings Totaling $775 Million
—$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing—
Oct 13, 2022 08:00 am ET
Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022
BRIDGEWATER, N.J., Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022.
Oct 07, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Oct. 7, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Oct 06, 2022 08:00 am ET
Insmed Holds Inaugural Global Day of Good - A Company-Wide Day of Service
— More than 500 Insmed employees volunteer across 13 sites in the U.S., Europe, and Japan —
Sep 07, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 7, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Sep 06, 2022 08:00 am ET
Insmed To Present at Two September Conferences
BRIDGEWATER, N.J., Sep. 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor events:
Aug 05, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Aug. 5, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Aug 04, 2022 07:30 am ET
Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch--
Jul 21, 2022 08:00 am ET
Insmed to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022
BRIDGEWATER, N.J., July 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2022 financial results on Thursday, August 4, 2022.
Jun 03, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 23, 2022 08:00 am ET
Insmed Names Drayton Wise Chief Commercial Officer
BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executi
May 17, 2022 06:05 pm ET
Insmed Presents New Data Across Three Pillars at American Thoracic Society 2022 International Conference
—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Initiation in Real-World Settings—
May 17, 2022 08:00 am ET
Insmed To Present at the H.C. Wainwright Annual Global Life Sciences Conference
BRIDGEWATER, NJ,, May 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.
May 06, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., May 6, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 05, 2022 07:30 am ET
Insmed Reports First Quarter 2022 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million--
Apr 21, 2022 08:00 am ET
Insmed to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
BRIDGEWATER, N.J., April 21, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2022 financial results on Thursday, May 5, 2022.
Apr 07, 2022 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., April 7, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 20 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Mar 28, 2022 08:00 am ET
Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference
--Real-World Evidence Evaluating Reduction in Hospitalizations Following Initiation of use of ARIKAYCE® (amikacin liposome inhalation suspension) to be Presented in Poster Discussion Session--
Mar 04, 2022 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., March 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Mar 03, 2022 07:00 am ET
Insmed To Present at the Cowen 42nd Annual Health Care Conference
BRIDGEWATER, N.J., March 3, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 at 9:10 a.m. ET.
Feb 17, 2022 06:00 am ET
Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update
BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's business and pipeline.
Feb 10, 2022 07:00 am ET
Insmed To Present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference
BRIDGEWATER, N.J., Feb. 10, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference on February 18, 2022 at 10:00 a.m. ET.
Feb 04, 2022 03:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Feb. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 27, 2022 07:00 am ET
Insmed to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Provide a Business and Pipeline Update on Thursday, February 17, 2022
BRIDGEWATER, N.J., Jan. 27, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022.
Jan 04, 2022 07:00 am ET
Insmed To Present at the 40th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 4, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 p.m. ET.
Dec 06, 2021 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Dec. 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to six new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 05, 2021 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 03, 2021 08:00 am ET
Insmed To Participate in Three November Conferences
BRIDGEWATER, N.J., Nov. 3, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor conferences:
Oct 28, 2021 04:05 pm ET
Insmed Ranks No. 1 on Science's 2021 Top Biopharma Employers List
BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has ranked as the top company to work for in Science's 2021 Top Employers Survey. The annual survey polls employees in the global biotech and pharmaceutical industry to determine the 20 best employers, as well as their driving characteristics.
Oct 28, 2021 07:30 am ET
Insmed Reports Third Quarter 2021 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Oct. 28, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.  
Oct 14, 2021 08:00 am ET
Insmed to Host Third Quarter 2021 Financial Results Conference Call on Thursday, October 28, 2021
BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2021 financial results on Thursday, October 28, 2021.
Oct 05, 2021 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Oct. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Sep 03, 2021 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 3, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Sep 01, 2021 08:00 am ET
Insmed To Participate in Five September Conferences
BRIDGEWATER, N.J., Sept. 1, 2021 /PRNewswire/ -- Insmed Incorporated Inc. (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:
Aug 06, 2021 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Aug. 6, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to eight new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Aug 05, 2021 07:30 am ET
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
Jul 27, 2021 08:00 am ET
Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021
BRIDGEWATER, N.J., July 27, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021.
Jul 08, 2021 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., July 8, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Feb 25, 2021 06:30 am ET
Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a business update.  
Feb 24, 2021 07:00 am ET
Insmed to Present at Two March Conferences
BRIDGEWATER, N.J., Feb. 24, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following virtual investor events:
Feb 19, 2021 06:30 am ET
Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)
BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the Phase 1 study of treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. Data from the study demonstrated that TPIP was generally safe and well tolerated, with a pharmacokinetic profile that supports once-daily dosing. A conference call will be held today, February 19, 2021, at 8:30 am ET, with Insmed management to further discuss these resul
Feb 16, 2021 07:00 am ET
Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study
BRIDGEWATER, N.J., Feb. 16, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release topline data from its Phase 1 healthy volunteer trial of treprostinil palmitil inhalation powder (TPIP) on Friday, February 19, 2021.
Feb 12, 2021 07:00 am ET
Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021
BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.
Feb 05, 2021 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Feb. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 14 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 05, 2021 07:00 am ET
Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference
BRIDGEWATER, N.J., Jan. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:30 a.m. ET.
Jan 04, 2021 07:00 am ET
Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease
BRIDGEWATER, N.J., Jan. 4, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient was dosed in late December, 2020, in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). The program consists of ARISE, an interventional study designed to validate cross-sectional and longitudinal characterist
Dec 04, 2020 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Dec. 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Dec 02, 2020 07:00 am ET
Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
BRIDGEWATER, N.J., Dec. 2, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient has been dosed in the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis. Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of bronchiectasis and other inflammatory diseases.
Nov 24, 2020 07:00 am ET
Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the virtual Evercore ISI 3rd Annual HealthCONx Conference on Tuesday, December 1, 2020 at 8:00 a.m. ET.
Nov 13, 2020 07:00 am ET
Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to brensocatib for the treatment of non-cystic fibrosis bronchiectasis (NCFBE). Brensocatib is a novel, first-in-class, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of NCFBE and other inflammatory diseases.
Nov 06, 2020 07:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Nov 02, 2020 07:00 am ET
Insmed to Present at Two November Conferences
BRIDGEWATER, N.J., Nov. 2, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following virtual investor conferences:
Oct 29, 2020 07:30 am ET
Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Oct. 29, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2020, and provided a business update.  
Oct 28, 2020 07:37 am ET
European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Trea
BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the European Commission (EC) has granted marketing authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion ("ARIKAYCE") for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Consideration should be given to official guidance on the a
Oct 20, 2020 08:00 am ET
Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020
BRIDGEWATER, N.J., Oct. 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2020 financial results on Thursday, October 29, 2020.
Aug 07, 2020 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Aug. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Aug 06, 2020 07:30 am ET
Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a business update.  
Jul 27, 2020 08:00 am ET
Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020
BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2020 financial results on Thursday, August 6, 2020.
Jul 24, 2020 07:36 am ET
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
BRIDGEWATER, N.J., July 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. Cons
Jul 07, 2020 08:00 am ET
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that ARIKAYCE® (amikacin liposome inhalation suspension) has been included in the new international treatment guidelines for nontuberculous mycobacterial (NTM) lung disease, a chronic, debilitating condition that can cause severe, permanent damage to the lungs. The evidence-based guidelines, issued by the American Thoracic Society (ATS), European Respiratory Society (ERS), European
Jul 06, 2020 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., July 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jun 24, 2020 04:01 pm ET
Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
BRIDGEWATER, N.J., June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that final results from the Phase 2 WILLOW study of brensocatib (formerly INS1007) in patients with non-cystic fibrosis bronchiectasis (NCFBE) were presented during a virtual American Thoracic Society (ATS) session titled Breaking News: Clinical Trial Results in Pulmonary Medicine. Brensocatib is a novel, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed
Jun 08, 2020 08:00 am ET
Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
BRIDGEWATER, N.J., June 8, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for brensocatib (formerly known as INS1007) for the treatment of adult patients with non-cystic fibrosis bronchiectasis (NCFBE) for reducing exacerbations. Brensocatib is a novel oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) currently being developed by Insmed for the treatme
Jun 05, 2020 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., June 5, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 26, 2020 08:00 am ET
Insmed to Present at Two June Conferences
BRIDGEWATER, N.J., May 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the following virtual investor conferences:
May 20, 2020 09:29 am ET
Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session
BRIDGEWATER, N.J., May 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new data from the Phase 2 WILLOW study of brensocatib (formerly known as INS1007) in non-cystic fibrosis bronchiectasis (NCFBE) will be presented during a virtual clinical trials session hosted by the American Thoracic Society (ATS) on Wednesday, June 24, 2020, at 2:00 pm ET. Data will be presented by lead study investigator James Chalmers, MBChB, Ph.D., Professor and Consulta
May 07, 2020 10:46 am ET
Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
BRIDGEWATER, N.J., May 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today the closing of the previously announced public offering of 11,155,000 shares of its common stock, including 1,455,000 shares issued pursuant to the exercise in full of the underwriters' option to purchase additional shares, at a public offering price of $23.25 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, were approximately $259.4 million.
May 07, 2020 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., May 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 05, 2020 08:00 am ET
Insmed Announces Pricing of Public Offering of Common Stock
BRIDGEWATER, N.J., May 5, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,700,000 shares of its common stock at a price to the public of $23.25 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $225.5 million. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,455,000 shares of common stock.
May 04, 2020 04:01 pm ET
Insmed Announces Proposed Public Offering of Common Stock
BRIDGEWATER, N.J., May 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Insmed. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size
Apr 30, 2020 07:30 am ET
Insmed Reports First Quarter 2020 Financial Results and Provides Business Update
BRIDGEWATER, N.J., April 30, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2020, and provided a business update.  
Apr 23, 2020 06:00 am ET
Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial
BRIDGEWATER, N.J., April 23, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will provide funding and clinical drug supply for the STOP-COVID19 (Superiority Trial of Protease inhibition in COVID-19) trial, an investigator-initiated study of brensocatib (formerly known as INS1007) in up to 300 hospitalized patients with COVID-19 sponsored by the University of Dundee. The study, which has been prioritized and designated an Urgent Public Health trial
Apr 20, 2020 08:00 am ET
Insmed to Host First Quarter 2020 Financial Results Conference Call on Thursday, April 30, 2020
BRIDGEWATER, N.J., April 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2020 financial results on Thursday, April 30, 2020.
Apr 03, 2020 08:00 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., April 3, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 13 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Apr 02, 2020 08:00 am ET
Insmed Appoints Carol A. Schafer to its Board of Directors
BRIDGEWATER, N.J., April 2, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets, and currently serves as a Managing Partner at Hyphen Advisors, LLC.
Mar 16, 2020 04:01 pm ET
Insmed Provides Business Update
BRIDGEWATER, N.J., March 16, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided a general business update.
Nov 14, 2019 07:00 am ET
Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer
BRIDGEWATER, N.J., Nov. 14, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Clarissa Desjardins, Ph.D., to its Board of Directors. Dr. Desjardins has more than 20 years of leadership experience in biotechnology, pharmaceuticals and research, and currently serves as President and Chief Executive Officer of Clementia Pharmaceuticals Inc., recently acquired by Ipsen S.A.
Nov 05, 2019 07:00 am ET
Insmed to Present at Two November Conferences
BRIDGEWATER, N.J., Nov. 5, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
Nov 04, 2019 03:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Oct 30, 2019 07:30 am ET
Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a business update.  
Oct 23, 2019 08:00 am ET
Insmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019
BRIDGEWATER, N.J., Oct. 23, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.
Oct 07, 2019 04:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 15 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Sep 05, 2019 04:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 5, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to six new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Sep 03, 2019 08:00 am ET
Insmed to Present at Two September Conferences
BRIDGEWATER, N.J., Sept. 3, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the following investor conferences:
Aug 02, 2019 04:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Aug. 2, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to five new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Aug 01, 2019 07:30 am ET
Insmed Reports Second Quarter 2019 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2019 and provided a business update.
Jul 25, 2019 08:00 am ET
Insmed to Host Second Quarter 2019 Financial Results Conference Call on Thursday, August 1, 2019
BRIDGEWATER, N.J., July 25, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2019 financial results on Thursday, August 1, 2019.
Jul 02, 2019 04:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., July 2, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to four new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
May 24, 2019 11:27 am ET
Insmed Announces Closing of Public Offering of Common Stock
BRIDGEWATER, N.J., May 24, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) today announced the closing of the previously announced public offering of its common stock. Insmed issued and sold in the public offering 9,615,385 shares of common stock, at a public offering price of $26.00 per share, resulting in gross proceeds of approximately $250.0 million. Insmed's net proceeds from the offering, after deducting estimated offering expenses and underwriting discounts and commissions, were approximately $235.5 million.  The underwriters have been granted 30-day options to purchase up to
May 21, 2019 08:56 pm ET
Insmed Announces Pricing of Public Offering of Common Stock
BRIDGEWATER, N.J., May 21, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it priced a registered underwritten public offering of 9,615,385 shares of its common stock, at a price to the public of $26.00 per share before underwriting discounts and commissions. Gross proceeds from the offering of these shares, before deducting underwriting discounts and commissions, are expected to be approximately $250.0 million.  The underwriters have been granted 30-day options to purchase up to an additional 1,042,307 shares of common stock from Insmed and up to 400,000 shares
May 20, 2019 04:05 pm ET
Insmed Announces Proposed Public Offering of Common Stock
BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM) announced today that it has commenced an underwritten public offering of up to $250 million of its common stock. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional $25.5 million of its common stock at the public offering price, less the underwriting discounts and commissions. William H. Lewis, the Company's Chairman and Chief Executive Officer, intends to grant the underwriters a 30-day option to purchase up to $12 million of Insmed common stock held by Mr. Le
May 20, 2019 04:01 pm ET
New Phase 3 Data Show Sustainability and Durability of Culture Conversion with ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with Refractory MAC Lung Disease
BRIDGEWATER, N.J., May 20, 2019 /PRNewswire/ -- Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today presented new data from the ongoing Phase 3 CONVERT study of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with refractory Mycobacterium avium complex (MAC) lung disease, demonstrating that the addition of ARIKAYCE to guideline-based therapy (GBT) was associated with sustained culture conversion through the end of treatment as well as durable culture conversion three month
May 07, 2019 07:30 am ET
Insmed Reports First Quarter 2019 Financial Results and Provides Business Update
BRIDGEWATER, N.J., May 7, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
Apr 30, 2019 08:00 am ET
Insmed to Host First Quarter 2019 Financial Results Conference Call on Tuesday, May 7, 2019
BRIDGEWATER, N.J., April 30, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first quarter 2019 financial results on Tuesday, May 7, 2019.
Apr 09, 2019 04:36 pm ET
Insmed Granted Additional U.S. Patent For ARIKAYCE® (amikacin liposome inhalation suspension), Strengthening Brand's Global Patent Portfolio
BRIDGEWATER, N.J., April 9, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,251,900 for certain uses of ARIKAYCE (amikacin liposome inhalation suspension). The claims of the patent relate in part to methods for treating Mycobacterium avium complex (MAC) lung disease via administration of ARIKAYCE to patients previously unresponsive to MAC therapy. This is the 10th patent issued by
Apr 08, 2019 05:00 am ET
Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch
BRIDGEWATER, N.J., April 8, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary net product sales for the first quarter of 2019.  ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug reg
Apr 03, 2019 07:50 am ET
Consolidated Research: 2019 Summary Expectations for Exxon Mobil, Chesapeake Energy, Booking, Insmed, Altair Engineering, and MobileIron — Fundamental Analysis, Key Performance Indications
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Exxon Mobil Corporation (NYSE:XOM), Chesapeake Energy Corporation...
Apr 02, 2019 04:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., April 2, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 12 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Apr 01, 2019 04:05 pm ET
Insmed To Showcase New ARIKAYCE® (amikacin liposome inhalation suspension) And Pipeline Data At American Thoracic Society International Conference
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that new Phase 3 data for ARIKAYCE® (amikacin liposome inhalation suspension) in Mycobacterium avium complex (MAC) lung disease will be presented as a late-breaker at the American Thoracic Society (ATS) International Conference, May 17-22, in Dallas. Additional data on ARIKAYCE as well as on Insmed's pipeline candidates will also be presented at the meeting.
Apr 01, 2019 08:00 am ET
Insmed to Present at the H.C. Wainwright Global Life Sciences Conference
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the H.C. Wainwright Global Life Sciences Conference in London on Monday, April 8, 2019 at 10:50 a.m. BST.
Mar 27, 2019 04:15 pm ET
Insmed Announces Management Changes
BRIDGEWATER, N.J., March 27, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Paolo Tombesi, Chief Financial Officer, will be leaving the company effective June 2, 2019, and will thereafter remain available on a consulting basis.  A search is under way for a new Chief Financial Officer. 
Mar 04, 2019 03:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., March 4, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to nine new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Feb 22, 2019 06:30 am ET
Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Feb. 22, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
Feb 20, 2019 07:00 am ET
Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference
BRIDGEWATER, N.J., Feb. 20, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Leerink Partners 8th Annual Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 3:30 p.m. ET.
Feb 15, 2019 07:00 am ET
Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019
BRIDGEWATER, N.J., Feb. 15, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its fourth quarter and year-end financial results on Friday, February 22, 2019.
Feb 07, 2019 07:50 am ET
Market Trends Toward New Normal in lululemon athletica inc, Insmed, Advanced Disposal Services, AGCO, Douglas Dynamics, and Ballard Power — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of lululemon athletica inc. (NASDAQ:LULU), Insmed, Inc. (NASDAQ:INSM),...
Feb 04, 2019 03:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Feb. 4, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 07, 2019 03:05 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Jan. 7, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to three new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
Jan 04, 2019 03:05 pm ET
Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019
BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary unaudited net product sales for the fourth quarter of 2018, and shared the Company's strategic priorities for 2019. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex
Dec 04, 2018 08:30 am ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ...
Nov 08, 2018 08:50 am ET
Consolidated Research: 2018 Summary Expectations for Insmed, Service Corporation International, EPR Properties, Nielsen Holdings Plc, NiSource, and Criteo S.A — Fundamental Analysis, Key Performance I
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Insmed, Inc. (NASDAQ:INSM), Service Corporation International...
Nov 08, 2018 08:30 am ET
Insmed Announces Changes to its Board of Directors
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced several changes to its board of directors.  Elizabeth McKee Anderson has been...
Nov 06, 2018 08:30 am ET
Insmed to Present at Three November Conferences
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will participate in the following investor conferences: The...
Oct 30, 2018 07:30 am ET
Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the third quarter ended September 30, 2018 and provided a...
Oct 23, 2018 08:30 am ET
Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its third quarter 2018 financial results on Tuesday, October 30, 2018. Insmed...
Oct 16, 2018 02:46 pm ET
Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), AAON, Inc. (NASDAQ:AAON),...
Oct 11, 2018 08:30 am ET
Insmed Presents New Data at IDWeek 2018 and CHEST Annual Meeting Enhancing the Understanding of MAC Lung Disease and Treatment with ARIKAYCE® (amikacin liposome inhalation suspension)
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Company presented data at IDWeek 2018 and at the CHEST Annual Meeting that provide additional...
Oct 04, 2018 04:30 pm ET
Insmed Extends Patent Protection in Japan to 2033
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Japanese Patent Office (JPO) has issued patent No. 6402097 for the Company’s amikacin liposome...
Oct 01, 2018 08:00 am ET
Insmed to Present at Two October Conferences
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will participate in the following investor conferences: The Cantor Fitzgerald Global...
Sep 28, 2018 05:58 pm ET
Insmed Announces FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Dise
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ARIKAYCE®...
Sep 17, 2018 08:00 am ET
Pivotal Phase 3 Data from CONVERT Study of ALIS in Patients with Treatment-Refractory NTM Lung Disease Caused by MAC Published in American Journal of Respiratory and Critical Care Medicine
--ALIS under FDA Priority Review with PDUFA action date of September 28, 2018-- BRIDGEWATER, N.J., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients...
Aug 17, 2018 07:35 am ET
Investor Expectations to Drive Momentum within Natural Resource Partners LP, Insmed, MagnaChip Semiconductor, Changyou, Pain Therapeutics, and Aurinia Pharmaceuticals — Discovering Underlying Factors
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Natural Resource Partners LP (NYSE:NRP), Insmed, Inc. (NASDAQ:INSM),...
Aug 07, 2018 05:30 pm ET
FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee voted 12 to 2...
Aug 02, 2018 07:30 am ET
Insmed Reports Second Quarter 2018 Financial Results and Provides Business Update
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the second quarter ended June 30, 2018 and provided a business update. “We are...
Jul 26, 2018 08:00 am ET
Insmed to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 2, 2018
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2018 financial results on Thursday, August 2, 2018. Insmed...
Jun 15, 2018 08:00 am ET
Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Division of Antimicrobial Products of the U.S. Food and Drug Administration (FDA) has notified...
Jun 07, 2018 08:00 am ET
Insmed to Present at Three June Conferences
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will present at the following investor conferences: The Nasdaq 38th Investor...
May 30, 2018 07:50 am ET
Recent Analysis Shows Northwest Natural Gas, Brooks Automation, Insmed, Host Hotels & Resorts, Prospect Capital, and Inphi Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northwest Natural Gas Company (NYSE:NWN), Brooks Automation, Inc....
May 22, 2018 05:15 pm ET
Insmed Announces Presentations at the American Thoracic Society 2018 International Conference
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that detailed data from its ongoing Phase 3 CONVERT study of ALIS (amikacin liposome inhalation...
May 17, 2018 04:05 pm ET
Insmed Appoints Leo Lee to its Board of Directors
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Leo Lee to its Board of Directors. Mr. Lee has more than 21 years of experience in...
May 16, 2018 08:00 am ET
Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the New Drug Application...
May 02, 2018 07:30 am ET
Insmed Reports First Quarter 2018 Financial Results and Provides Business Update
BRIDGEWATER, N.J., May 02, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the first quarter ended March 31, 2018 and provided a business...
May 01, 2018 08:00 am ET
Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference
BRIDGEWATER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present...
Apr 25, 2018 08:00 am ET
Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018
BRIDGEWATER, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2018 financial results on...
Apr 05, 2018 08:00 am ET
Research Report Identifies Brown & Brown, CorVel, Pacific Ethanol, HomeTrust Bancshares, FORTERRA INC, and Insmed with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brown & Brown, Inc. (NYSE:BRO), CorVel...
Mar 29, 2018 08:00 am ET
Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC
BRIDGEWATER, N.J., March 29, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has submitted its New Drug Application (NDA) for ALIS (Amikacin...
Mar 07, 2018 08:00 am ET
Insmed to Present at the Cowen and Company 38th Annual Health Care Conference
BRIDGEWATER, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that a member of the management team will present at the Cowen...
Feb 23, 2018 07:30 am ET
Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
BRIDGEWATER, N.J., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017 and...
Feb 23, 2018 06:45 am ET
Insmed Incorporated to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 23, 2018 / Insmed Incorporated (NASDAQ: INSM) will be discussing their earnings results in their Q4 Earnings Call to be held on February 23, 2018 at 8:30 AM Eastern Time.
Feb 21, 2018 05:26 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to 47 new employees. In accordance...
Feb 20, 2018 08:00 am ET
Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent
BRIDGEWATER, N.J., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S....
Feb 15, 2018 08:00 am ET
Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018
BRIDGEWATER, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its fourth quarter and year-end financial results...
Feb 12, 2018 07:40 am ET
Market Trends Toward New Normal in Insmed, Hudson Technologies, East West, Ringcentral, Armstrong Flooring, and Host Hotels & Resorts — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insmed, Inc. (NASDAQ:INSM), Hudson Technologies, Inc....
Feb 07, 2018 04:30 pm ET
Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference
BRIDGEWATER, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present at...
Jan 26, 2018 12:00 pm ET
Insmed Announces Closing of Public Offering
BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes due 2025.  Insmed issued and sold in the public offering $450...
Jan 24, 2018 05:31 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to 25 new employees. In accordance...
Jan 23, 2018 10:49 pm ET
Insmed Announces Pricing of Public Offering of Convertible Senior Notes
BRIDGEWATER, N.J., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced its registered underwritten public offering of $400 million aggregate principal amount of its 1.75% convertible senior notes due 2025.  Net proceeds from...
Jan 22, 2018 04:01 pm ET
Insmed Announces Proposed Public Offering of Convertible Senior Notes
BRIDGEWATER, N.J., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $300 million aggregate principal amount of convertible senior notes due 2025.  Insmed intends to grant the...
Jan 03, 2018 04:10 pm ET
Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Pr
BRIDGEWATER, N.J., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced new data from its Phase 3 clinical program for adult patients...
Nov 28, 2017 08:00 am ET
Insmed to Present at the Nasdaq 37th Annual Investor Conference
BRIDGEWATER, N.J., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed, will present...
Nov 22, 2017 04:30 pm ET
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to ten new employees. In accordance...
Nov 08, 2017 04:30 pm ET
Insmed to Present at Two November Conferences
BRIDGEWATER, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief Executive Officer of Insmed will present...
Nov 02, 2017 07:30 am ET
Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update
BRIDGEWATER, N.J, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the third quarter ended September 30, 2017 and provided a business...
Sep 11, 2017 04:01 pm ET
Insmed Announces Closing of Public Offering
BRIDGEWATER, N.J., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its common stock.  Insmed issued and sold in the public offering 14,123,150 shares of common stock, including 1,842,150 shares of common stock issued pursuant to the exercise on September 7, 2017 of the underwriters’ option to purchase additional shares, at a public offering price of $28.50 per share, resulting in gross proceeds of approximately $402.5 million. The net proceeds to Insmed from this offering were approximately $377.7...
Sep 06, 2017 10:31 am ET
Get A Stock Report On Disney, The Goldman Sachs Group, Hewlett Packard Enterprise Company, Insmed inc., Trivago, Or Any Stock You Choose.
CHICAGO, Sept. 6, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DIS, GS, HPE, INSM, and TRVG.
Jul 27, 2017 08:00 am ET
Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its second quarter 2017 financial results on Thursday, August 3, 2017....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.